PDF(Pubmed)
Abstract：
OBJECTIVE: This study aimed to comprehensively analyze the clinical characteristics and treatment status of Chinese small cell carcinoma of the ovary hypercalcemic type (SCCOHT) patients, providing insights into this unique population and comparing findings with international literature.
METHODS: Through a meta-analysis, we collected data from published case reports and records from the Obstetrics & Gynecology Hospital of Fudan University. Demographic information, clinical presentations, tumor attributes, treatment modalities, and survival outcomes were extracted and examined alongside relevant global studies.
RESULTS: The analysis encompassed 80 Chinese SCCOHT patients, of which 62 from 33 previously reported literatures, and the other 18 were from Obstetrics & Gynecology Hospital of Fudan University. In 62 cases with stage information, A total of 25 tumors were International Federation of Gynecology and Obstetrics stage I, 3 were stage II, 19 were stage III, and 15 were stage IV. Most patients received surgery and chemotherapy, but regimens were varied. Median follow-up was 10 months (range=4-120). Elevated carbohydrate antigen 125 and serum calcium levels were consistent findings. Recurrence rates were notable, especially among stage I patients. Platinum-based chemotherapy, paclitaxel and carboplatin (n=11, 13.4%), constituted common treatment regimens.
CONCLUSIONS: This study observed demographic and clinical similarities with international datasets. And the findings emphasize the urgency for innovative therapeutic approaches to improve outcomes in SCCOHT patients. Continued research efforts are essential to enhance the knowledge surrounding this rare malignancy and to optimize its clinical management.
METHODS: Through a meta-analysis, we collected data from published case reports and records from the Obstetrics & Gynecology Hospital of Fudan University. Demographic information, clinical presentations, tumor attributes, treatment modalities, and survival outcomes were extracted and examined alongside relevant global studies.
RESULTS: The analysis encompassed 80 Chinese SCCOHT patients, of which 62 from 33 previously reported literatures, and the other 18 were from Obstetrics & Gynecology Hospital of Fudan University. In 62 cases with stage information, A total of 25 tumors were International Federation of Gynecology and Obstetrics stage I, 3 were stage II, 19 were stage III, and 15 were stage IV. Most patients received surgery and chemotherapy, but regimens were varied. Median follow-up was 10 months (range=4-120). Elevated carbohydrate antigen 125 and serum calcium levels were consistent findings. Recurrence rates were notable, especially among stage I patients. Platinum-based chemotherapy, paclitaxel and carboplatin (n=11, 13.4%), constituted common treatment regimens.
CONCLUSIONS: This study observed demographic and clinical similarities with international datasets. And the findings emphasize the urgency for innovative therapeutic approaches to improve outcomes in SCCOHT patients. Continued research efforts are essential to enhance the knowledge surrounding this rare malignancy and to optimize its clinical management.
摘要：
目的：本研究旨在综合分析中国卵巢高血钙小细胞癌(SCCOHT)患者的临床特点及治疗现状。提供对这一独特人群的见解，并将发现与国际文献进行比较。
方法：通过荟萃分析，我们从复旦大学附属妇产科医院发表的病例报告和记录中收集数据.人口统计信息,临床表现,肿瘤属性，治疗方式，和生存结果被提取并与相关的全球研究一起检查。
结果：分析包括80名中国SCCOHT患者，其中33篇先前报道的文献中有62篇，其余18人来自复旦大学附属妇产科医院。在62个有阶段信息的案例中，共有25个肿瘤被国际妇产科联合会一期，3是第二阶段，19是第三阶段，15个是第四阶段。大多数患者接受了手术和化疗，但是方案是多种多样的。中位随访时间为10个月(范围=4-120)。升高的糖抗原125和血清钙水平是一致的发现。复发率显著，尤其是在I期患者中。铂类化疗,紫杉醇和卡铂（n=11，13.4%），构成常见的治疗方案。
结论：本研究观察到与国际数据集的人口统计学和临床相似性。研究结果强调了创新治疗方法改善SCCOHT患者预后的紧迫性。持续的研究工作对于增强围绕这种罕见恶性肿瘤的知识并优化其临床管理至关重要。
方法：通过荟萃分析，我们从复旦大学附属妇产科医院发表的病例报告和记录中收集数据.人口统计信息,临床表现,肿瘤属性，治疗方式，和生存结果被提取并与相关的全球研究一起检查。
结果：分析包括80名中国SCCOHT患者，其中33篇先前报道的文献中有62篇，其余18人来自复旦大学附属妇产科医院。在62个有阶段信息的案例中，共有25个肿瘤被国际妇产科联合会一期，3是第二阶段，19是第三阶段，15个是第四阶段。大多数患者接受了手术和化疗，但是方案是多种多样的。中位随访时间为10个月(范围=4-120)。升高的糖抗原125和血清钙水平是一致的发现。复发率显著，尤其是在I期患者中。铂类化疗,紫杉醇和卡铂（n=11，13.4%），构成常见的治疗方案。
结论：本研究观察到与国际数据集的人口统计学和临床相似性。研究结果强调了创新治疗方法改善SCCOHT患者预后的紧迫性。持续的研究工作对于增强围绕这种罕见恶性肿瘤的知识并优化其临床管理至关重要。
